<DOC>
	<DOCNO>NCT02087306</DOCNO>
	<brief_summary>This multicenter study Brincidofovir ( CMX001 ) ( BCV ) administer twice weekly ( BIW ) treatment AdV infection detect asymptomatic AdV viremia symptomatic AdV infection . After complete screen assessment confirm study eligibility , enrolled subject undergo treatment period 12 week . Beginning Day 1 , adult ( â‰¥ 18 year ) adolescent ( 13-17 year ) subject weigh &gt; 50 kg receive BCV 100 mg BIW ; child 12 year age receive weight-based dos 2 mg/kg BIW , not-to-exceed total dose 200 mg/week .</brief_summary>
	<brief_title>Phase III , Open-labeled , Multicenter Study Safety Efficacy Brincidofovir ( CMX001 ) Treatment Early Versus Late Adenovirus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<criteria>Patients undergone hematopoietic cell transplant ( HCT ) , solid organ transplant ( SOT ) Have primary severe immunodeficiency predisposes rapid progression disseminate AdV disease Must able ingest , absorb tolerate oral medication Willing able understand provide write informed consent . For minor incapable provide write informed consent ( i.e. , incapacitate ) , understood , write informed consent must provide parent legal guardian representative . To best ( parent/guardian ) knowledge , willing able participate require study activity duration study . Females pregnant currently nurse . Patients condition would , judgment investigator , put patient increase risk participation study , interfere conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Adenovirus Infection</keyword>
</DOC>